Your browser doesn't support javascript.
loading
A proof-of-concept study with SOM3355 (bevantolol hydrochloride) for reducing chorea in Huntington's disease.
Gamez, Josep; Calopa, Matilde; Muñoz, Esteban; Ferré, Aileen; Huertas, Oscar; McAllister, Kevin; Reig, Núria; Scart-Grès, Catherine; Insa, Raúl; Kulisevsky, Jaime.
Afiliação
  • Gamez J; Neurology Department, GMA Clinic, European Reference Network on Rare Neurological Diseases (ERN-RND), Autonomous University of Barcelona, Barcelona, Spain.
  • Calopa M; Movement Disorders Unit, Neurology Department, Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat, Barcelona, Spain.
  • Muñoz E; Parkinson's Disease and Movement Disorders Unit, Neurology Service, Institut Clínic de Neurociències, Hospital Clínic de Barcelona, University of Barcelona, Barcelona, Spain.
  • Ferré A; European Reference Network for Rare Neurological Diseases (ERN-RND), Tübingen, Germany.
  • Huertas O; SOM Innovation Biotech SA, Barcelona, Spain.
  • McAllister K; SOM Innovation Biotech SA, Barcelona, Spain.
  • Reig N; Neurenable GmbH, Basel, Switzerland.
  • Scart-Grès C; SOM Innovation Biotech SA, Barcelona, Spain.
  • Insa R; SOM Innovation Biotech SA, Barcelona, Spain.
  • Kulisevsky J; SOM Innovation Biotech SA, Barcelona, Spain.
Br J Clin Pharmacol ; 89(5): 1656-1664, 2023 05.
Article em En | MEDLINE | ID: mdl-36494329
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Coreia / Doença de Huntington Tipo de estudo: Clinical_trials / Prognostic_studies Limite: Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Coreia / Doença de Huntington Tipo de estudo: Clinical_trials / Prognostic_studies Limite: Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article